Skip to main content
보도자료 배포 뉴스와이어
검색폼
검색
로그인
회원가입
보도자료
서비스
교육
블로그
보도자료 배포
보도자료 구독
고객센터
보도자료 배포 서비스
보도자료 배포 뉴스와이어
보도자료 배포
보도자료 구독
고객센터
로그인
회원가입
보도자료
서비스
교육
블로그
통합검색
보도자료
사진
동영상
기업
박람회
FAQ
취소
기업 검색
보도자료 등록
최신
IT
건강
경제
교육
금융
농수산
라이프
레저
문화
미디어
부동산
사회
산업
스포츠
에너지
운송
유통
자동차
정책
신상품
상장기업
주요
최신 보도자료
MY뉴스
상장기업
사진
동영상
기업뉴스룸
박람회
인기 토픽
보도자료 분야와 RSS
English News
산업별
IT
건강
경제
교육
금융
농수산
라이프 스타일
레저
문화/연예
미디어
산업별
부동산
사회
산업
스포츠
에너지/환경
운송
유통
자동차
정책/정부
주제별
개발
공모/모집
기업문화
부고
분양
사업계획
사회공헌
선언/의견
설립/오픈
소송
수상/선정
수주
주제별
신상품
실적
인물동정
인사
인수/합병
전시/출품
정책
제휴
조사연구
채용
투자
판촉활동
지역별
서울
인천/경기
대전/충남
광주/전남
부산/울산/경남
대구/경북
강원
충북
전북
제주
해외
기업 뉴스룸
Boehringer Ingelheim International GmbH
이 회사 보도자료 구독
제약
INGELHEIM, Germany
http://www.boehringer-ingelheim.com
Boehringer Ingelheim International GmbH 보도자료
337개
RSS
이메일
2016년 6월 13일
11:50
New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
New analyses showed risk reductions were consistent across age groups for cardiovascular (CV) outcomes, including CV death, with Jardiance® (empagliflozin) compared with placebo when added to standard of care in adults with type 2 diabetes (T2D) and
건강
제약
개발
2016년 6월 13일
10:50
New study results show Trajenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
Results from the MARLINA-T2DTM trial demonstrated that Trajenta® (linagliptin), which is marketed by Boehringer Ingelheim and Eli Lilly and Company, reduced blood sugar in adults with type 2 diabetes (T2D) who are at risk for kidney impairment with a
건강
제약
개발
2016년 6월 8일
09:55
Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases
Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute’s - Harvard Fibrosis Network to discover new ways of treating fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), chronic
건강
제약
제휴
2016년 6월 7일
11:45
New data on olmutinib (BI 1482694) presented at ASCO 2016 underscores clinical potential of Boehringer Ingelheim’s next generation lung cancer compound
Boehringer Ingelheim will announce updated results from the Phase II part of the HM-EMSI-101 [NCT01588145] trial at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, U.S. The study investigates the safety and efficacy
건강
제약
개발
2016년 6월 3일
11:50
Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising lung cancer compound olmutinib
Boehringer Ingelheim has initiated the ELUXA trial programme, designed to further investigate the therapeutic potential of olmutinib* (BI 1482694 / HM61713), a novel third-generation, epidermal growth factor receptor (EGFR) mutation-specific tyrosine
건강
제약
개발
2016년 5월 31일
18:45
Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
Boehringer Ingelheim and Inventiva, a French biopharmaceutical company specialised in the development of innovative therapies for fibrosis, oncology and orphan diseases, announced today, a new multi-year research and drug discovery collaboration and
건강
제약
제휴
2016년 5월 27일
13:05
3 out of 4 people with symptomatic asthma report reduced productivity at work
Not for distribution to UK/US/Canadian media Results were released today by Boehringer Ingelheim from an international survey, providing new insight into the negative impact of persistent asthma symptoms on people’s work productivity and their abi
건강
제약
조사연구
2016년 5월 25일
11:00
IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease
Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn’s disease with investigational biologic, risankizumab (formerly BI 655066), a compound from Boehringer Ingelheim research and
건강
제약
개발
2016년 5월 23일
17:50
Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
Boehringer Ingelheim and BioMed X announced today that they have established a new research team of outstanding scientists from around the world that will conduct research to identify novel approaches for the treatment of patients with psychiatric di
건강
제약
제휴
2016년 5월 18일
12:05
South Korea is first to approve next generation lung cancer treatment olmutinib (BI 1482694 / HM61713)
Olmutinib* (BI 1482694 / HM61713) has been approved in South Korea for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer, who had been previously t
건강
제약
개발
2016년 5월 17일
17:30
New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Broad Range of Patients with IPF
New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).[1-4] In total, Boehringer Ingelheim presented 12
건강
제약
개발
2016년 5월 12일
14:15
Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
Boehringer Ingelheim will undertake the first prospective, randomised controlled study of a non-vitamin K antagonist oral anticoagulant (NOAC) in patients with blood clots in the veins or venous sinuses of the brain. RE-SPECT CVT® will investigate th
건강
제약
개발
2016년 5월 11일
18:35
Boehringer Ingelheim: Nine out of 10 AF patients are concerned about stroke and many want to be part of OAC treatment decisions, new international survey shows
Nine out of 10 patients with atrial fibrillation (AF) surveyed were concerned about the risk of a stroke.[1] Oral anticoagulant (OAC) treatments are usually prescribed to reduce this risk3 and the vast majority of patients actively sought information
건강
제약
개발
2016년 5월 9일
17:05
LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma
Boehringer Ingelheim today announced the enrolment of the first patient in the global Phase III trial evaluating the efficacy and safety of nintedanib in combination with pemetrexed/cisplatin, followed by continuing nintedanib monotherapy, as a first
건강
제약
개발
2016년 4월 20일
14:15
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine Jardiance® (empagliflozin) for the treatment of people with chronic heart failure. The trials are target
건강
제약
개발
2016년 4월 13일
16:30
Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced NSCLC published in The Lancet Oncology
Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology Results from LUX-Lung 7, a
건강
제약
개발
2016년 4월 8일
16:35
The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids
Boehringer Ingelheim today announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not benefit from the addition of ICS treatment.[1] In WISDOM, for 80 percent of pa
건강
제약
개발
2016년 4월 7일
16:50
Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung
Boehringer Ingelheim today announced that the European Commission (EC) has granted marketing authorisation for Giotrif® (afatinib) for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung whose disease has progressed on
건강
제약
개발
2016년 4월 4일
16:40
Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations
Boehringer Ingelheim has announced the results of a new interim analysis of data from the ongoing phase III RE-VERSE AD™ patient study that showed a single 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran, the activ
건강
제약
개발
2016년 3월 24일
10:50
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim today announces the enrollment of the first patient in RE-COVERY DVT/PE™, a global observational study on the management of blood clots in the legs (deep vein thrombosis, DVT) and in the lungs (pulmonary embolism, PE). The new st
건강
제약
조사연구
2016년 3월 8일
18:00
New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma - Regardless of Allergy Subtype[1,2,3]
Boehringer Ingelheim today announced the presentation of new post-hoc analyses that show the addition of SPIRIVA® (tiotropium) Respimat® to other asthma maintenance therapies helps improve lung function and asthma symptom control, while reducing asth
건강
제약
개발
2016년 3월 8일
12:10
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie (NYSE:ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. AbbVie and Boehringer Ingelheim also are evalu
건강
제약
제휴
2016년 3월 2일
09:40
European Committee for Medicinal Products for Human Use recommends approval of Giotrif® (afatinib) for advanced squamous cell cancer of the lung
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) (http://goo.gl/fbcEKu) issued a positive opinion (http://goo.gl/iVpYzS) for the approval of Giotrif® (http://go
건강
제약
개발
2016년 2월 29일
17:40
New survey gives voice to people living with a rare and devastating lung disease: “When I think of IPF I think of breathlessness”
An international survey of over 500 people living with idiopathic pulmonary fibrosis (IPF) in more than 20 countries worldwide reveals the real-life emotions faced by those with the devastating disease.[1] IPF affects approximately 3 million people w
건강
제약
조사연구
2016년 2월 26일
14:30
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
Pooled analysis from the TOMORROW and INPULSIS® trials, recently published in Respiratory Medicine, provides further evidence that OFEV® (nintedanib) significantly reduces the risk of acute exacerbations by 47% in people with idiopathic pulmonary fib
건강
제약
개발
이전
6
7
8
9
10
다음
동영상
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine
회사 보도자료 구독
뉴스와이어 회원은 이 회사 보도자료를 이메일과
MY뉴스
를 통해 무료로 구독할 수 있습니다.
회원 가입하기